Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which steroid best fights ARDS? a Head-to-Head trial aims to find out

NCT ID NCT06496997

Disease control Sponsor: Fayoum University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This trial tests three steroid drugs, methylprednisolone, dexamethasone, and hydrocortisone, in people with acute respiratory distress syndrome (ARDS), a severe lung condition that often requires a ventilator. The goal is to see if one steroid works better than the others at reducing deaths within 28 days. Researchers will also track how many patients need a ventilator, how long they stay in the ICU and hospital, and any side effects like infections or high blood sugar. The study enrolls adults on mechanical ventilation who meet the standard criteria for ARDS.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Three steroid drugs: methylprednisolone, dexamethasone, and hydrocortisone
What this could lead to
If one steroid proves more effective, it could become the preferred treatment for ARDS, potentially improving survival and reducing time on a ventilator.
What could go wrong
This is a mid-stage trial, so results may not be conclusive. Steroids carry risks like infections and high blood sugar, and the best drug may not clearly emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

195 people

The number who actually took part.

Started

Aug 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: We include patients receiving mechanical ventilation for hypoxemic respiratory failure if they met the diagnostic criteria for ARDS according to the American-European Consensus definition, as later reclassified on the basis of the 2012 Berlin criteria for the diagnosis of ARDS, defined as: 1. Presence of acute hypoxemic respiratory failure (an arterial oxygen partial pressure to fraction of inspired oxygen ratio (PaO2/FiO2) of ≤ 300 mm Hg, requiring supplemental oxygen administrated by simple face mask, nasal cannula, or other similar oxygen-delivery device to maintain oxygen saturation at greater than 93% within the first 48 h of the onset of ARDS) 2. Onset within 7 days of insult, or new (within 7 days) or worsening respiratory symptoms 3. Bilateral opacities on chest x-ray or CT not fully explained by effusions, lobar or lung collapse, or nodules 4. Cardiac failure not the primary cause of acute respiratory failure Exclusion Criteria: We exclude patients with acute hypoxemic respiratory failure caused by congestive heart failure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute respiratory distress syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute respiratory distress syndrome

Contacts and locations

Locations

  • Fayoum University

    Al Fayyum, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.